Literature DB >> 88679

Suppression and reversal of allergic encephalomyelitis in rhesus monkeys with basic protein and peptides.

E H Eylar, J J Jackson, P J Kniskern.   

Abstract

We have extended earlier studies on the suppression of clinically evident experimental allergic encephalomyelitis (EAE) in monkeys, repeated injections of human basis protein. The results confirm that after suppressive treatment, recovered animals remain clinically normal and do not show spontaneous recurrence of symptoms. However, recovered animals are susceptible to EAE upon renewed challenge, and they develop the disease more rapidly and more severely than after the initial challenge; resuppression is also accomplished in these cases by the same methods used previously. The results indicate further that the basic protein or peptide T administered without mycobacteria is effective in suppressing the development of basic protein-induced EAE regardless of the species from which it was derived.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 88679     DOI: 10.1007/BF00964148

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  31 in total

1.  ENCEPHALITOGEN-INDUCED INHIBITION OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS: PREVENTION, SUPPRESSION AND THERAPY.

Authors:  E C ALVORD; C M SHAW; S HRUBY; M W KIES
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen.

Authors:  D Teitelbaum; C Webb; A Meshorer; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1973-05       Impact factor: 5.532

3.  Specific cleavage of the A1 protein from myelin with cathepsin D.

Authors:  S W Brostoff; W Reuter; M Hichens; E H Eylar
Journal:  J Biol Chem       Date:  1974-01-25       Impact factor: 5.157

4.  Allergic encephalomyelitis: cleavage of the C-tryptophyl bond in the encephalitogenic basic protein from bovne myelin.

Authors:  E H Eylar; G A Hashim
Journal:  Arch Biochem Biophys       Date:  1969-04       Impact factor: 4.013

5.  Suppression of chronic allergic encephalomyelitis: relevance to multiple sclerosis.

Authors:  C S Raine; U Traugott; S H Stone
Journal:  Science       Date:  1978-08-04       Impact factor: 47.728

6.  Failure of basic protein therapy for multiple sclerosis.

Authors:  R E Gonsette; P Delmotte; L Demonty
Journal:  J Neurol       Date:  1977-08-18       Impact factor: 4.849

7.  Protection against experimental allergic encephalomyelitis with peptides derived from myelin basic protein: presence of intact encephalitogenic site is essential.

Authors:  B F Driscoll; M W Kies; E C Alvord
Journal:  J Immunol       Date:  1976-07       Impact factor: 5.422

8.  Allergic encephalomyelitis in monkeys induced by a peptide from the A1 protein.

Authors:  E H Eylar; S Brostoff; J Jackson; H Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1972-03       Impact factor: 11.205

9.  Multiple sclerosis: sensitization of a myelin basic protein fragment (peptide T) encephalitogenic to primates. A preliminary report.

Authors:  W Sheremata; E H Eylar; J B Cosgrove
Journal:  J Neurol Sci       Date:  1977-06       Impact factor: 3.181

10.  Experimental allergic encephalitis. Dissociation of cellular immunity to brain protein and disease production.

Authors:  L E Spitler; C M Von Muller; H H Fudenberg; E H Eylar
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

View more
  2 in total

1.  Calcium Signalling Triggered by NAADP in T Cells Determines Cell Shape and Motility During Immune Synapse Formation.

Authors:  Merle Nebel; Bo Zhang; Francesca Odoardi; Alexander Flügel; Barry V L Potter; Andreas H Guse
Journal:  Messenger (Los Angel)       Date:  2015-06

2.  Absence of reuptake of serotonin influences susceptibility to clinical autoimmune disease and neuroantigen-specific interferon-gamma production in mouse EAE.

Authors:  H H Hofstetter; R Mössner; K P Lesch; R A Linker; K V Toyka; R Gold
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.